DDInter810 DDInter782
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Gefitinib {u} (Compound) resembles {v} (Compound) Erlotinib
Gefitinib {u} (Compound) treats {v} (Disease) lung cancer
Gefitinib {u} (Compound) binds {v} (Gene) CYP2D6
Gefitinib {u} (Compound) upregulates {v} (Gene) ZNF589
Gefitinib {u} (Compound) downregulates {v} (Gene) IFRD2
Gefitinib {u} (Compound) causes {v} (Side Effect) Appetite absent
Gefitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danazol
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Gefitinib (Compound) resembles Bosutinib (Compound)
Gefitinib (Compound) resembles Erlotinib (Compound)
Gefitinib (Compound) treats lung cancer (Disease)
Gefitinib (Compound) binds CYP2D6 (Gene)
Gefitinib (Compound) upregulates ZNF589 (Gene)
Gefitinib (Compound) downregulates IFRD2 (Gene)
Gefitinib (Compound) causes Appetite absent (Side Effect)
Gefitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Danazol
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene